JP2024525665A - 効率的なゲノム編集のための組成物及び方法 - Google Patents

効率的なゲノム編集のための組成物及び方法 Download PDF

Info

Publication number
JP2024525665A
JP2024525665A JP2024501179A JP2024501179A JP2024525665A JP 2024525665 A JP2024525665 A JP 2024525665A JP 2024501179 A JP2024501179 A JP 2024501179A JP 2024501179 A JP2024501179 A JP 2024501179A JP 2024525665 A JP2024525665 A JP 2024525665A
Authority
JP
Japan
Prior art keywords
seq
sequence
domain
prime editing
editing composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525665A5 (cg-RX-API-DMAC10.html
Inventor
リース,ホリー・エイ
パッカー,マイケル
バーレラ,ルイス
スレイメーカー,イアン
Original Assignee
プライム・メディスン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プライム・メディスン・インコーポレイテッド filed Critical プライム・メディスン・インコーポレイテッド
Publication of JP2024525665A publication Critical patent/JP2024525665A/ja
Publication of JP2024525665A5 publication Critical patent/JP2024525665A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024501179A 2021-07-06 2022-06-29 効率的なゲノム編集のための組成物及び方法 Pending JP2024525665A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163218744P 2021-07-06 2021-07-06
US63/218,744 2021-07-06
US202163219623P 2021-07-08 2021-07-08
US63/219,623 2021-07-08
PCT/US2022/035613 WO2023283092A1 (en) 2021-07-06 2022-06-29 Compositions and methods for efficient genome editing

Publications (2)

Publication Number Publication Date
JP2024525665A true JP2024525665A (ja) 2024-07-12
JP2024525665A5 JP2024525665A5 (cg-RX-API-DMAC10.html) 2025-07-07

Family

ID=84800962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501179A Pending JP2024525665A (ja) 2021-07-06 2022-06-29 効率的なゲノム編集のための組成物及び方法

Country Status (6)

Country Link
US (1) US20240228988A1 (cg-RX-API-DMAC10.html)
EP (1) EP4367227A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024525665A (cg-RX-API-DMAC10.html)
AU (1) AU2022306377A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224970A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023283092A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
WO2023039586A1 (en) * 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
EP4444362A4 (en) 2021-12-10 2026-04-01 Flagship Pioneering Innovations Vi Llc CFTR COMPOSITIONS AND MODULATION METHODS
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences
CN117511906A (zh) * 2023-03-14 2024-02-06 中国农业大学 一种高效的Csy4核酸酶切割介导的多基因引导编辑系统CMPE及相关蛋白
WO2024249584A2 (en) * 2023-05-31 2024-12-05 University Of Massachusetts Improved modular prime editing with modified effectors and templates
WO2024259051A1 (en) * 2023-06-14 2024-12-19 The Children's Medical Center Corporation Systems and methods for modifying a polynucleotide
WO2025038881A1 (en) * 2023-08-16 2025-02-20 Beam Therapeutics Inc. Prime editing of single base mutations in sickle cell disease
WO2025076306A1 (en) * 2023-10-06 2025-04-10 University Of Massachusetts Prime editors having improved prime editing efficiency
WO2025194133A1 (en) 2024-03-15 2025-09-18 Beam Therapeutics Inc. Prime editing of single base mutations in alpha-1 antitrypsin deficiency
WO2025226946A1 (en) * 2024-04-24 2025-10-30 Cedric Francois Methods and compositions for the treatment of androgenic alopecia
WO2025231071A1 (en) * 2024-05-01 2025-11-06 Beam Therapeutics Inc. Compositions and methods for cell conditioning

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116051A1 (en) * 2017-12-15 2019-06-20 Autolus Limited Plasmid system
WO2020191233A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2021042047A1 (en) * 2019-08-30 2021-03-04 The General Hospital Corporation C-to-g transversion dna base editors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339385B2 (en) * 2018-03-25 2022-05-24 GeneTether, Inc. Modified nucleic acid editing systems for tethering donor DNA
WO2020033083A1 (en) * 2018-08-10 2020-02-13 Cornell University Optimized base editors enable efficient editing in cells, organoids and mice
JP7646552B2 (ja) * 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
JP7518549B2 (ja) * 2019-02-02 2024-07-18 シャンハイテック ユニバーシティ 遺伝子編集における非意図的な変異の阻害
US20230051661A1 (en) * 2019-12-26 2023-02-16 Agency For Science, Technology And Research Nucleobase Editors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116051A1 (en) * 2017-12-15 2019-06-20 Autolus Limited Plasmid system
WO2020191233A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191248A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Method and compositions for editing nucleotide sequences
WO2021042047A1 (en) * 2019-08-30 2021-03-04 The General Hospital Corporation C-to-g transversion dna base editors

Also Published As

Publication number Publication date
EP4367227A1 (en) 2024-05-15
AU2022306377A1 (en) 2024-01-25
EP4367227A4 (en) 2025-04-30
US20240228988A1 (en) 2024-07-11
CA3224970A1 (en) 2023-01-12
WO2023283092A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US20240228988A1 (en) Compositions and methods for efficient genome editing
US20240067940A1 (en) Methods and compositions for editing nucleotide sequences
US20240011007A1 (en) Genome editing compositions and methods for treatment of chronic granulomatous disease
US20240424138A1 (en) Genome editing compositions and method for treatment of retinitis pigmentosa
US20250297246A1 (en) Modified prime editing guide rnas
AU2022283964A1 (en) Genome editing compositions and methods for treatment of wilson's disease
EP4504921A2 (en) Methods and compositions for editing nucleotide sequences
US20240229038A1 (en) Genome editing compositions and methods for treatment of wilson's disease
US20240360476A1 (en) Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy
EP4419688A2 (en) Genome editing compositions and methods for treatment of usher syndrome type 3
US20250011766A1 (en) Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis
WO2024178144A1 (en) Methods and compositions for editing nucleotide sequences
WO2023086842A1 (en) Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy
US20240376466A1 (en) Genome editing compositions and methods for treatment of fanconi anemia
EP4658781A2 (en) Genome editing compositions and methods for treatment of cystic fibrosis
US20250354138A1 (en) Prime editing of single base mutations in alpha-1 antitrypsin deficiency
WO2025038881A1 (en) Prime editing of single base mutations in sickle cell disease
CN117999347A (zh) 用于高效基因组编辑的组合物和方法
EP4658322A1 (en) Genome editing compositions and methods for treatment of cystic fibrosis
WO2025090637A2 (en) Genome editing compositions and methods for treatment of retinitis pigmentosa
EP4437102A1 (en) Genome editing compositions and methods for treatment of glycogen storage disease type 1b
WO2025231071A1 (en) Compositions and methods for cell conditioning

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260515